Results 31 to 40 of about 192,309 (409)
Standardized warfarin monitoring decreases adverse drug reactions
BMC Family Practice, 2019 Background While warfarin is the most commonly prescribed medication to prevent thromboembolic disorders, the risk of adverse drug reactions (ADR) poses a serious concern.
Lisa B. E. Shields +6 more
doaj +1 more source
Thrombosis Journal, 2008 Introduction Atrial fibrillation affects an estimated 2.5 million Americans and incurs an average annual stroke risk of 4.5% per year. Despite warfarin reducing stroke risk by approximately 66%, prior studies show warfarin usage rates to be about 50 ...
Cavalcante Joao +5 more
doaj +1 more source
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Blood, 2018 Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid ...
V. Pengo +21 more
semanticscholar +1 more source
JAMA Network Open, 2020 Key Points Question What is the role of warfarin in preventing ischemic strokes in patients with atrial fibrillation and end-stage renal disease? Findings This meta-analysis found that, although the current literature is only observational, warfarin use ...
M. Randhawa +6 more
semanticscholar +1 more source
Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]
, 2019 © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ +7 more
core +2 more sources
Warfarin pharmacogenetics [PDF]
Trends in Cardiovascular Medicine, 2015 The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes have been strongly and consistently associated with warfarin dose requirements, and dosing algorithms incorporating genetic and clinical information have been shown to be predictive of stable warfarin dose.
Julie A, Johnson, Larisa H, Cavallari
openaire +2 more sources
Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report
Journal of Pharmaceutical Health Care and Sciences, 2023 Background Alectinib, crizotinib, and ceritinib, are anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) that exhibit high protein binding, and their metabolism is associated with the cytochrome P450 (CYP) isoenzymes 2C9 or 3A4.
Takashi Kato +10 more
doaj +1 more source
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
ADMET and DMPK, 2021 Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan +2 more
doaj +1 more source
Warfarin dose estimation on multiple datasets with automated hyperparameter optimisation and a novel software framework [PDF]
Journal of Biomedical Informatics, 2020, 2019 Warfarin is an effective preventative treatment for arterial and venous thromboembolism, but requires individualised dosing due to its narrow therapeutic range and high individual variation. Many machine learning techniques have been demonstrated in this domain.
arxiv +1 more source
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
New England Journal of Medicine, 2009 BACKGROUND The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism.
S. Schulman +8 more
semanticscholar +1 more source